Position in ABBV
as of Jun 30, 2026
· filed Jul 13, 2026
Position Value
$632,874
-$1,635,981 QoQ
Shares Held
2,515
-75.9% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.28%
of 13F equity value
Holder Rank
#2,957
of 4,153 holders
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FCG Investment Co holds $10,776,926 across 7 Drug Manufacturers - General names. ABBV ranks #6 (5.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
2,688 | $3,224,068 | |
| 2 | JNJ |
Johnson & Johnson
|
8,748 | $2,221,729 | |
| 3 | BMY |
Bristol Myers Squibb Co
|
34,461 | $1,985,642 | |
| 4 | MRK |
Merck & Co., Inc.
|
12,049 | $1,548,296 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
6,223 | $786,213 | |
| 6 | ABBV |
AbbVie Inc.
This page
|
2,515 | $632,874 | |
| 7 | PFE |
Pfizer Inc
|
15,702 | $378,104 |
All Filings in ABBV
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $632,874 | 2,515 | Shares | Sole | 2026-07-13 | |
| 2026-03-31 | $2,268,855 | 10,432 | Shares | Sole | 2026-04-09 | |
| 2025-09-30 | $2,615,475 | 11,296 | Shares | Sole | 2025-10-08 | |
| 2025-06-30 | $2,205,351 | 11,881 | Shares | Sole | 2025-07-16 | |
| 2025-03-31 | $2,666,351 | 12,726 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $2,169,361 | 12,208 | Shares | Sole | 2025-01-17 | |
| 2024-09-30 | $2,300,839 | 11,651 | Shares | Sole | 2024-10-24 | |
| 2024-06-30 | $1,275,422 | 7,436 | Shares | Sole | 2024-07-16 | |
| 2024-03-31 | $1,413,460 | 7,762 | Shares | Sole | 2024-04-19 | |
| No filing history on record for this holder in this stock. | ||||||